Ocrelizumab: Completed Phase II enrollment

The partners completed enrollment of 200 patients in a 96-week, dose-finding Phase II trial evaluating 600 mg of ocrelizumab, 1,000 mg of ocrelizumab, 1 cycle of placebo followed by ocrelizumab, or 1 ...